Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Descriptive oxidative and lipid-related fluorescence observations associated with Esketamine treatment in a high-concentration NMDA-exposed HT-22/C8-D1A co-culture model.

Toxicology in vitro : an international journal published in association with BIBRA·2026

Same author

Corrigendum to "Cipepofol attenuates endothelial barrier dysfunction in acute lung injury through DUSP1-dependent suppression of MAPK signaling" [Biochem. Pharmacol. 250 (2026) 117995].

Biochemical pharmacology·2026

Same author

Intracellular lipid droplets positively regulate the dormancy of colorectal cancer cells depending on ELF1-ACSL5 signaling.

Journal of experimental & clinical cancer research : CR·2026

Same author

Corrigendum to "Cipepofol attenuates endothelial barrier dysfunction in acute lung injury through DUSP1-dependent suppression of MAPK signaling" [Biochem. Pharmacol. 250 (Pt 1) (2026) 117995].

Biochemical pharmacology·2026

Same author

Machine learning model-guided selective use of temporary diverting ileostomy in rectal cancer surgery: a randomized controlled trial.

Nature communications·2026

Same author

Activation of endothelial GABA<sub>A</sub> receptor α1 subunit protects against barrier dysfunction in acute lung injury.

BMC pulmonary medicine·2026

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Suppression of dual-specificity phosphatase 6 protects against liver fibrosis via targeting CYP2E1-mediated

Can Jiang¹, Xiaoli Tang², Ziyang Xu³

¹Department of Anesthesiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.

International Journal of Biological Macromolecules

|December 29, 2025

Summary

Dual-specificity phosphatase 6 (DUSP6) promotes liver fibrosis by suppressing ferroptosis. Inhibiting DUSP6 or CYP2E1 improves liver fibrosis and protects hepatocytes, offering new therapeutic targets for liver disease.

Keywords:

DUSP6 Ferroptosis Liver fibrosis

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Area of Science:

Biochemistry
Cell Biology
Pathology

Background:

Dual-specificity phosphatase 6 (DUSP6) is implicated in liver disorders.
Understanding DUSP6's role in liver fibrosis is crucial for developing treatments.

Purpose of the Study:

To investigate the role of DUSP6 in liver fibrosis.
To elucidate the underlying molecular mechanisms involving the ERK and ferroptosis pathways.

Main Methods:

Carbon tetrachloride (CCl4)-induced mouse model of liver fibrosis.
Dusp6 knockdown experiments (in vivo and in vitro).
Transcriptomic analysis, Western blotting, and cell-based assays.

Main Results:

DUSP6 was upregulated in liver fibrosis and its knockdown ameliorated fibrosis.
DUSP6 knockdown increased ferroptosis proteins (SLC7A11, GPX4) and suppressed Cyp2e1.
DUSP6 knockdown enhanced ERK phosphorylation, hepatocyte proliferation, and ferroptosis resistance, while reducing injury.

Conclusions:

DUSP6 promotes liver fibrosis by inhibiting ferroptosis and regulating the ERK/CYP2E1 axis.
Targeting DUSP6 or CYP2E1 shows therapeutic potential for liver fibrosis.